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Abstract: Carfilzomib is a selective, irreversible proteasome inhibitor, initially approved in the 
US in 2012 as single-agent therapy for relapsed and refractory multiple myeloma. Numerous 
Phase II studies have evaluated carfilzomib in the relapsed and refractory as well as the newly 
diagnosed setting, and Phase III studies are entering their final analysis. Data continue to grow 
to support its use as both single-agent therapy and in combination with immunomodulatory and 
other novel agents. This review discusses the role of carfilzomib in the treatment of multiple 
myeloma. Its mechanism of action, pharmacokinetics, and role in clinical management will 
be reviewed.
Keywords: relapsed and refractory, targeted therapy, proteasome inhibitor, novel agents
Introduction
Multiple myeloma (MM), a clonal plasma cell disorder, is the second-most common 
hematological malignancy. Incidence in the US is estimated at 24,000 people annually, 
with 11,000 deaths expected in 2014.1 Significant recent progress in the treatment of 
MM has led to clinical improvements in progression-free survival (PFS) and overall 
survival (OS).
While MM was once a rapidly progressive disease, initial progress was made 
with the introduction of melphalan and steroid combination therapy in the 1960s. The 
subsequent advent of autologous stem cell transplantation (ASCT) and novel agents, 
including the proteasome inhibitors and immunomodulatory agents, further extended 
OS. Continued progress is ongoing, with Surveillance Epidemiology and End Results 
(SEER) data showing death rates falling 1.7% per year over the past decade.
The upfront treatment of patients with novel agents has now become the standard of 
care for induction therapy in transplant-eligible and -ineligible patients.2  Nevertheless, 
responses are temporary and relapse is nearly universal. With disease progression, 
the majority of patients become resistant to prior lines of therapy, underlining the 
importance of new and effective treatments.3
A potent and highly selective proteasome inhibitor, carfilzomib is an effective and 
tolerable therapy for patients with MM. In 2012, it was granted fast-track approval 
by the US Food and Drug Administration for the treatment of MM patients who have 
received at least two prior therapies, including bortezomib and an immunomodula-
tory agent, and have demonstrated disease progression on or within 60 days of the 
completion of the last therapy. The data supporting its utility and safety continue to 
grow as further studies investigate its use in the up-front, relapsed and refractory, and 
combination-therapy settings.





Proteasome pathway  
and carfilzomib
The ubiquitin–proteasome pathway is a crucial cellular 
housekeeping pathway responsible for the degradation 
and removal of regulatory cellular proteins. It has a central 
role in the regulation of cell-cycle progression and cellular 
 senescence. Targeted proteins are enzymatically polyubiquit-
inated, marking them for degradation by the 26S proteasome. 
The 26S  proteasome consists of two 19S regulatory com-
plexes, capping a central 20S proteolytic core. Ubiquitinated 
proteins are guided into the 20S core after recognition by a 
19S complex. Major catalytic activities of the 20S core include 
a chymotrypsin-like (ChT-L) activity found in the β5 subunit, 
a trypsin-like activity in the β2 subunit, and a caspase-like 
activity in the β1 subunit.4 ChT-L activity has been shown to 
be the rate-limiting step of proteolysis in vitro and in vivo.5
Carfilzomib is an irreversible, epoxyketone proteasome 
inhibitor that specifically targets the ChT-L activity of the 
20S proteasome.6 Epoxyketones are derivatives of epoxo-
micin, a natural product isolated from actinomycetes that 
forms an irreversible, selective, and highly specific adduct 
with the N-terminal threonine of the ChT-L β5 subunit of 
the 20S proteolytic core.7
Compared with the reversible inhibitor bortezomib, 
carfilzomib is a covalent inhibitor with greater in vitro 
selectivity and less off-target activity.8 Furthermore, it has 
been shown to be active in cell lines that are resistant to 
bortezomib and other available therapies.6 This enhanced 
inhibition of proteasome function leads to the accumulation 
of proteins targeted for degradation and subsequent cellular 
apoptosis.9,10
Preclinical studies
Due to the superior specificity of carfilzomib when compared 
to prior proteasome inhibitors, it was expected that preclini-
cal tests would show improved proteasome inhibition and 
enhanced antitumor activity. Initial tests utilizing purified 
extracts of human 20S enzyme showed carfilzomib to have a 
dose-dependent inhibition of ChT-L proteolytic activity. This 
dose-dependent inhibition persisted when investigations were 
pursued utilizing intact mammalian cells.9
Most cell culture-based studies evaluating cytotoxicity 
of prior proteasome inhibitors showed effective proapoptotic 
effects, but utilized long incubation times (24–72 hours) 
that were unrealistic mirrors of in vivo activity. Carfilzomib, 
however, showed impressive proteasome inhibition and cyto-
toxicity in hematologic tumor cell lines with short incubation 
times (1 hour).9
Furthermore, activity in MM cell lines showed  effective 
induction of apoptosis in cultured tumor cells, including 
significant activity in bortezomib-resistant cell lines.11 
 Comparisons between carfilzomib and bortezomib performed 
via tumor xenografts in immunocompromised mouse models 
showed improved efficacy over bortezomib, with carfilzomib 




Key pharmacokinetic and pharmacodynamic studies 
were performed in two Phase I studies: PX-171-001 and 
PX-171-002. These trials found that carfilzomib is rapidly 
metabolized to inactive metabolites, with minimal reliance 
on the cytochrome P450 pathway. The mean elimination 
half-life was generally less than 30 minutes. Observed rates 
of clearance exceeded hepatic blood flow, suggesting that 
carfilzomib is largely cleared extrahepatically, possibly by 
multiple pathways.12–14
There was wide variation in both intra- and interpatient 
carfilzomib plasma concentrations, possibly due to differ-
ences in administration and monitoring. Both the maximum 
concentration and area under the curve increased with dose, 
but not in a dose-proportional manner. The volume of dis-
tribution at a steady state suggested wide tissue distribution 
in both studies.12–14
Pharmacodynamic studies evaluated inhibition of the 
20S ChT-L proteasome activity in both whole blood and 
peripheral blood mononuclear cells (PBMCs). Samples taken 
1 hour after dosing with 15 mg/m2 revealed more than 70% 
inhibition in PBMCs. At 27 mg/m2, approximately 90% inhi-
bition was seen in PBMCs. In PX-171-002, which evaluated 
dosing on 2 consecutive days for 3 weeks of a 4-week cycle, 
proteasome inhibition after the second dose was equivalent to 
or greater than that seen with the first dose. In PX-171-001, 
which evaluated 5-day consecutive dosing on 2-week cycles, 
proteasome inhibition was observed at greater than 90% on 
the 5th day of dosing. Recovery of proteasome activity was 
seen in PBMCs prior to the second cycle of dosing on both 
schedules.12–14
Use in relapsed and refractory 
multiple myeloma
Single agent
Approval for carfilzomib was based on the results of the 
Phase IIB PX-171-003-A1 trial, enrolling relapsed and refrac-
tory MM (RRMM) patients who had been previously treated 
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with both bortezomib and an immunomodulatory drug. With 
257 evaluable patients, this trial examined carfilzomib’s efficacy 
in a heavily pretreated population (median of five prior thera-
pies) that was highly bortezomib-resistant (74%).  Carfilzomib 
was found to have an overall response rate (ORR) of 23.7%, 
improving to 37% when minimal responses (MRs) were 
included. Duration of response was 7.8 months, with median 
time-to-progression of 3.9 months and an OS of 15.6 months. 
Treatment-related grade 3–4 adverse events (AEs) were primar-
ily fatigue (7.5%), acute kidney injury (3.4%), and dyspnea 
(3.4%). Hematologic grade 3–4 AEs included anemia (24%) 
and thrombocytopenia (29%).15 Given its tolerable safety pro-
file and proven efficacy, carfilzomib was granted a fast-track 
approval following the results of this pivotal Phase II study.
Prior to PX-171-003-A1, initial pharmacokinetics 
and toxicity were examined in two Phase I clinical trials: 
 PX-171-001 and PX-171-002. The maximum tolerated dose 
(MTD) in PX-171-001 was 15 mg/m2 (carfilzomib dosed on 
days 1–5 every 14 days), and in PX-171-002 the MTD was 
not reached with patients receiving 20 mg/m2 in week 1 and 
27 mg/m2 in subsequent weeks (dosing on days 1, 2, 8, 9, 
15, and 16 of 28-day cycles). In PX-171-001, grade 3 febrile 
neutropenia and grade 4 thrombocytopenia were observed, 
establishing the MTD at 15 mg/m2. PX-171-002 used an 
alternative dosing strategy, with grade 3–4 AEs primarily 
consisting of anemia, thrombocytopenia, and fatigue. Due to 
its improved tolerability, PX-171-002 set the standard dose 
regimen for further investigations.12,13
In the pivotal PX-171-003-A1 study, doses of carfilzomib 
were administered at 20–27 mg/m2, with each dose given 
over a period of up to 10 minutes. Building on animal data 
suggesting improved tolerability with prolonged infusion 
times, Papadopoulos et al investigated an alternative dosing 
strategy in a subsequent Phase I study. In this trial, 33 patients 
were assigned to receive carfilzomib over 30 minutes at doses 
escalating from 20 mg/m2 through 70 mg/m2. MTD was 
defined as 56 mg/m2, with dose-limiting toxicities of renal 
tubular necrosis and proteinuria (grade 3) in two patients at 
70 mg/m2. The ORR was 50% for patients treated at 56 mg/m2 
(12 patients). The addition of low-dose dexamethasone (40 mg 
weekly); increased the ORR to 55% among 22 patients treated 
at 45 or 56 mg/m2. Toxicities were minimal, and largely con-
sisted of grade 1–2 anemia and thrombocytopenia. Peripheral 
neuropathy was rare. This confirmed the apparent safety and 
efficacy of a dose-escalated regimen. Investigation into opti-
mal dosing continues.16
Further studies examined carf ilzomib’s role in 
 bortezomib-naïve patients. In the Phase II PX-171-004 study, 
single-agent carfilzomib was evaluated in 165 patients with 
relapsed and/or refractory MM who had received one to three 
previous lines of therapy. A total of 129 patients with refrac-
tory, bortezomib-naïve MM were assigned to successive treat-
ment cohorts. Initial dosing with 20 mg/m2 was subsequently 
dose-escalated to 27 mg/m2. The ORR was found to be 42% 
for patients treated with 20 mg/m2 over 12 cycles, and 52% 
for patients treated with 20 mg/m2 for one cycle followed by 
27 mg/m2 for cycles 2–12. When MRs were included, the 
ORR increased to 59% for the lower-dose cohort and 64% for 
the higher-dose cohort. Time to progression was not reached 
in the 27 mg/m2 group versus 8.3 months in the 20 mg/m2 
group. Treatment-emergent AEs of all grades included fatigue 
(62%), dyspnea (38.8%), diarrhea (31%), anemia (41.9%), 
and thrombocytopenia (30.2%). Peripheral neuropathy was 
rare (17.1%) and did not limit treatment.17
Results from pivotal Phase III studies are in the early 
stages of reporting data evaluating carfilzomib’s efficacy. In 
the FOCUS trial, a randomized, controlled, Phase III trial, 
315 patients with RRMM were enrolled across several inter-
national centers. Patients were randomly allocated to one of 
two treatment regimens: single-agent carfilzomib versus a 
steroid optionally combined with oral  cyclophosphamide. 
The majority of patients allocated to steroids received 
 cyclophosphamide. Enrolled patients had been heavily pre-
treated with a median of five prior lines of therapy.  Preliminary 
reports have revealed that there was no statistically significant 
OS difference between the two arms. As of yet, no actual 
numbers for OS or PFS have been reported in the literature, 
and full details are pending final publication. Safety data 
have likewise not yet been released, but reportedly the rate of 
cardiac events was consistent with prior cohorts.18
Combination therapy
Given its limited off-target effects and favorable safety pro-
file, carfilzomib is an attractive agent for use in combination 
treatment. 
The CHAMPION-1 trial is a Phase I, dose-escalation 
study investigating weekly carfilzomib in combination with 
dexamethasone for RRMM patients. Patients were treated 
with carfilzomib on days 1, 8, and 15 of each 28-day cycle 
with an initial dose of 20 mg/m2 and subsequent cycles 
starting at 45 mg/m2, with dose-escalation cohorts of 56, 70, 
and 88 mg/m2. Dexamethasone was given weekly on days 
1, 8, 15, and 22 for the first eight cycles, after which day 
22  dexamethasone was omitted. A total of 18 patients were 
enrolled, with two dose-limiting toxicities observed at the 
88 mg/m2 dose level. The ORR was 67% with four complete 





responses (CR), one very good partial response (VGPR), five 
partial responses (PR) and three minimal responses (MR). 
Overall, the weekly dosing at 70 mg/m2 demonstrated a com-
parable half-life and higher area under the curve per cycle 
compared with the currently approved twice-weekly dosing 
regimen. More data are necessary to confirm this MTD and 
response data. Safety data were significant for two patients 
with grade 3 acute kidney injury, as well as one patient each 
with grade 3 dyspnea, pneumonia, and hyponatremia.19
Further examining the role of carfilzomib in combination 
with dexamethasone, Lendvai et al evaluated the efficacy of 
this combination in a small cohort of a Phase II study. In this 
trial, patients with RRMM failing to achieve at least a PR 
after two cycles of carfilzomib were assigned to dexametha-
sone in addition to carfilzomib. A total of 34 patients were 
treated with eleven requiring the addition of dexamethasone. 
Additional responses were limited, with four of the eleven 
patients eventually achieving a PR and continuing treatment 
for an average of an additional 4.5 cycles.20
The Phase IB/II PX-171-006 study examined the combi-
nation of carfilzomib, lenalidomide, and dexamethasone in 
patients with relapsed or progressive MM with one to three 
lines of previous therapy. MTD was determined for the com-
bination in the Phase IB portion (carfilzomib 20/27 mg/m2, 
lenalidomide 25 mg, and dexamethasone 40 mg). Follow-
ing a Phase II expansion, there were 84 total patients, 52 of 
whom were treated at the MTD. At a median of 24.4 months 
of follow-up, the ORR was 69% in the overall population and 
76.9% in the patients treated at the MTD. Median PFS was 
reported at 11.8 months, with a median duration of response 
of 18.8 months. Grade 3–4 AEs included lymphopenia 
(48.1%), neutropenia (32.7%), fatigue (7.1%), and diarrhea 
(6%). Grade 3–4 dyspnea and peripheral neuropathy were 
rare, at 1.2% each.21,22
Building on the role of carfilzomib in combination with 
immunomodulatory agents, Shah et al evaluated the combina-
tion of carfilzomib and pomalidomide with dexamethasone 
(Car-Pom-d). In a Phase I/II study evaluating a heavily 
pretreated population of RRMM patients, the Car-Pom-d 
regimen was well tolerated and achieved a high response 
rate (ORR of 64%, $MR rate of 81%). Of the 72 enrolled 
patients, all were lenalidomide-refractory and 87% had prior 
bortezomib exposure.23
Additional novel combinations utilizing carfilzomib are 
under investigation in RRMM. A Phase I study has been 
presented evaluating ARRY-520, a kinesin spindle protein 
inhibitor, in combination with carfilzomib in patients with 
RRMM. ARRY-520 was administered intravenously on days 
1, 2, 15, and 16 in combination with carfilzomib (days 1, 2, 
8, 9, 15, and 16) on 28-day cycles. Of a total of 20 patients, 
19 were evaluable for outcomes. The ORR ($MR) was 58%, 
with one patient having a near-CR (nCR) and six patients 
with a PR. Toxicity was limited and the combination was well 
tolerated, with six episodes of pneumonia and one episode 
each of febrile neutropenia and bacteremia.24
Early Phase III data are also in preliminary stages for 
combination therapy. The ASPIRE trial is a randomized, 
multicenter, open-label Phase III trial assessing the differ-
ences in PFS among relapsed MM patients enrolled onto 
treatment with carfilzomib in combination with lenalidomide 
and dexamethasone (KRd) compared to lenalidomide and 
dexamethasone alone. Patients were treated with carfilzomib 
dosed at 20 mg/m2 on days 1 and 2 of cycle 1, then 27 mg/m2 
for subsequent doses. Both arms received lenalidomide at 
25 mg per day for 21 days of a 28-day cycle in combination 
with dexamethasone (Rd). Initial prepublication reports of a 
planned interim analysis show that with a total of 792 patients 
enrolled at over 100 treatment centers, the PFS for KRd was 
26.3 months, a statistically significant improvement over 
17.6 months for those in the Rd regimen. There was a trend 
toward improvement in OS in KRd, although this was not 
statistically significant at this time. Full presentation of the 
trial data is still pending final publication. No new concerns 
were raised by preliminary safety data, with similar rates of 
AEs as seen in previous trials.25
Upfront treatment
An ongoing area of investigation, the use of carfilzomib in the 
upfront setting promises to improve response rates and extend 
PFS and OS. Several studies have already reported the results 
of carfilzomib in the treatment of newly diagnosed MM.
In a Phase I/II study by Jakubowiak et al, both trans-
plant-eligible and -ineligible newly diagnosed MM patients 
were evaluated. Patients on this study were enrolled onto 
induction therapy with carfilzomib, lenalidomide, and 
dexamethasone (KRd). Patients received up to eight cycles 
of induction therapy with carfilzomib dosed at 20, 27, or 
36 mg/m2, lenalidomide at 25 mg, and dexamethasone at 
40 mg (cycles 1–4) and 20 mg (cycles 5–8). Transplant-
eligible patients were able to move to transplant (seven 
proceeded to transplant and 35 had stem cell collection 
after cycle 4). Patients could continue KRd until cycle 24. 
With a median follow-up of 25 months, the ORR was 98%, 
with a CR rate of 64%. At 2 years, the estimated PFS was 
94% and OS was 98%. Overall treatment was tolerated in 
patients, with a limited number of AEs.26
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Another trial evaluating both transplant-eligible 
and - ineligible patients is examining the role of carfilzomib, 
clarithromycin, lenalidomide, and dexamethasone as combi-
nation therapy for newly diagnosed MM. Newly diagnosed 
patients were treated with carfilzomib (days 1, 2, 8, 9, 15, 
and 16 of 28-day cycles) and dexamethasone 40 mg weekly. 
Treatment continued until a response plateau was achieved 
(no change in M protein for two cycles). Transplant-eligible 
patients proceeded to ASCT, and ineligible patients went 
straight to consolidation therapy. All patients received con-
solidation treatment with clarithromycin 500 mg twice daily, 
lenalidomide 25 mg daily on days 1–21, and dexamethasone 
40 mg weekly in 28-day cycles. Consolidation continued until 
a second plateau was achieved, followed by lenalidomide 
maintenance (10 mg daily on days 1–21 of 28-day cycles). 
Of a total of 23 evaluable patients, at 30.8 weeks of median 
 follow-up, the ORR was 87%, with 9% achieving a strin-
gent CR (sCR), 39% attaining a VGPR, and 35% showing 
at least a PR. A total of five patients came off therapy due 
to grade 3 renal failure (two patients), grade 3 congestive 
heart failure (CHF; two patients), and a grade 3 venous 
thromboembolism.27
The combination of carfilzomib, lenalidomide, and dex-
amethasone followed by lenalidomide maintenance was inves-
tigated in newly diagnosed transplant-eligible and - ineligible 
MM patients. Patients were initiated onto treatment with carfil-
zomib 20/36 mg/m2 (days 1, 2, 8, 9, 15, and 16), lenalidomide 
(25 mg orally days 1–21), and dexamethasone (20/10 mg on 
days 1, 2, 8, 9, 15, 16, 22, and 23). Patients eligible for trans-
plant underwent stem cell collection after cycle 4. Following 
eight cycles of induction, patients with at least stable disease 
received up to 24 cycles of lenalidomide (10 mg on days 1–21 
of 28-day cycles). A total of 41 patients were enrolled, and 
after a median of nine cycles, 63% had at least a CR, 26% 
had a VGPR, and 8% had a PR. With a median follow-up of 
10 months, PFS was 83.3%. Minimal residual disease (MRD) 
negativity was also assessed, with 100% of the 17 patients 
achieving a CR also found to be negative by MRD testing. 
Among those attaining at least a VGPR, 63% had evidence of 
abnormal plasma cells by MRD assessment.28
The CARTHADEX trial evaluated the combination of 
carfilzomib, thalidomide, and dexamethasone (CTD) for 
induction and consolidation therapy in transplant-eligible 
patients with newly diagnosed MM. Patients were treated 
with CTD for four cycles with thalidomide 200 mg on days 
1–28, dexamethasone 40 mg on days 1, 8, 15, and 22, and 
carfilzomib dosed differently in three cohorts (20–45 mg/m2). 
Following transplantation, patients underwent consolidation 
with four cycles of CTD. The primary end point was 
VGPR after four cycles of CTD. The results of the first two 
 carfilzomib-dose cohorts have been reported (20/27 mg/m2 
and 36 mg/m2). With a total of 70 patients included, and 
median follow-up of 22 and 7 months, the ORR was 96%. 
After induction therapy, 19% of patients achieved a CR 
or sCR, and 60% had at least a VGPR. The CR/sCR rate 
improved to 30% after ASCT and to 49% after consolidation 
therapy. The PFS was 74% in the evaluated population, with 
median follow-up as noted earlier. The regimen was well 
tolerated, with grade 3–4 nonhematologic toxicity observed 
in ,5% of patients, primarily infection and rash.29
The CYCLONE trial is a Phase I/II study evaluat-
ing carfilzomib combination therapy in newly diagnosed 
 transplant-eligible MM patients. Enrolled patients are 
assigned to induction therapy with a combination of 
 carfilzomib (15–45 mg/m2 on days 1, 2, 8, 9, 15, and 16), 
thalidomide (100 mg on days 1–28), cyclophosphamide 
(300 mg/m2 on days 1, 8, and 15), and dexamethasone 
(40 mg weekly). As of the most recent publication, with a 
total of 54 patients, the ORR was 91%, with 18% achieving 
a CR and 58% a VGPR. Minimal toxicities were reported, 
with primarily grade 1 neuropathy and minimal cardiac or 
pulmonary effects. With a median follow-up of 16 months, 
1-year PFS was 90% and 1-year OS was 98%.30
Role in special populations
Asymptomatic patients
Given MM’s easily observable precursor state, the role of 
early treatment for patients nearing a diagnosis of MM has 
been an ongoing clinical question. For these asymptomatic 
or “smoldering” MM patients, there have been multiple trials 
evaluating the efficacy of intervention. This remains an area 
of ongoing clinical investigation without clear evidence to 
guide clinical practice.
Investigating the role of carfilzomib in the asymp-
tomatic patient, Landgren et al undertook a single-arm 
Phase II trial for patients with high-risk smoldering MM. 
Patients were treated with carfilzomib in combination with 
 lenalidomide and dexamethasone, followed by 2 years of 
lenalidomide maintenance therapy. High-risk smolder-
ing MM was defined by the PETHEMA or Mayo criteria. 
 Carfilzomib was given in 28-day cycles at 20/36 mg/m2 
on days 1, 2, 8, 9, 15, 16, 22, and 23. After eight cycles of 
induction, patients with a response consistent with stable 
disease or better received lenalidomide maintenance (10 mg 
daily on days 1–21) for 2 years. Twelve patients were 
enrolled, with an ORR of 100% (five sCRs, two CRs, two 





nCRs, and three VGPRs), with no patients progressing to 
symptomatic MM during the study. Evaluation of MRD 
showed six of seven patients achieving at least a CR to 
be negative by MRD assessment. The most common tox-
icities were rash (17%), CHF (8%), dyspnea (8%), and 
 lymphopenia (33%). Larger clinical studies and further 
follow-up are needed, but these results show impressive 
response in the smoldering MM setting.31
Renal impairment
Often a defining characteristic, renal dysfunction is a com-
mon feature of MM. Its development has been associated with 
worse prognosis and shortened survival, limiting the available 
treatment options and often requiring dose reductions.32
To assess the safety and efficacy of carfilzomib in 
patients with renal impairment, the Phase II PX-171-
005 trial enrolled relapsed/refractory or progressive MM 
patients who had been treated with at least two prior 
 regimens. A total of 50 patients were enrolled and strati-
fied by creatinine clearance (.80 mL/min, 50–80 mL/min, 
30–49 mL/min, ,30 mL/min and chronic hemodialysis). 
A total of 33 of these patients (66%) were refractory to 
prior bortezomib therapy. Carfilzomib was given on days 
1, 2, 8, 9, 15, and 16 in 28-day cycles, with the following 
dose escalation: 15 mg/m2 (cycle 1), 20 mg/m2 (cycle 2), and 
27 mg/m2 (cycle 3+). The primary goal was the assessment 
of pharmacokinetics, with secondary outcomes including 
safety, tolerability, and efficacy.33
In the final analysis, there were no differences in carfil-
zomib clearance or exposure among patients with impaired 
renal function versus those with normal renal function. Grade 
3/4 AEs were limited to anemia (28%), thrombocytopenia 
(20%), lymphopenia (18%), and fatigue (14%), and were 
similar among groups. The ORR was 25.5%, with a median 
duration of response of 7.9 months.33
There appears to be no differences in carfilzomib clear-
ance or exposure among patients with normal renal function 
and those with renal impairment. Additionally, the safety 
of carfilzomib was not influenced by the degree of baseline 
renal impairment, with carfilzomib being well tolerated and 
showing promising efficacy in all groups.33
Elderly and transplant-ineligible
Age is the greatest risk factor for the development of MM, 
with the disease incidence increasing steadily to a peak 
of more than 40 per 100,000 people in those older than 
80 years.34 The accumulation of additional comorbidities with 
advancing age makes this subpopulation an important area 
for active research to improve outcomes. The initial trials of 
single-agent carfilzomib enrolled patients with a median age 
of 63.5 years (PX-171-003-AO), 63 years (PX-171-003-A1), 
and 65 years (PX-171-004), suggesting its efficacy and toler-
ability in an older population.15,17,35
Combination therapies including carf ilzomib 
have shown encouraging tolerability and activity in 
patients $65 years of age. A Phase II study by Bringhen 
et al evaluated the efficacy and safety of the combination 
of carfilzomib, cyclophosphamide, and dexamethasone in 
elderly patients ($65 years of age) or those ineligible for 
ASCT. A total of 58 patients were enrolled and received 
this combination for up to nine cycles, followed by main-
tenance single-agent carfilzomib.  Maintenance continued 
until progression or intolerance. Following a median of 
nine cycles of induction (range 1–9), a total of 20% of 
patients achieved an sCR and 49% had attained an nCR. 
The ORR was excellent, with 95% of patients with at least 
a PR and 71% with a VGPR. With a median follow-up of 
18 months, the 2-year PFS was 76% and the OS rate was 
87%. The regimen had an acceptable safety profile in this 
population of older, transplant-ineligible patients. The 
most frequent reported toxicity was fever (32%), with 
peripheral neuropathy being rare (8%) and relatively mild 
(grade 1–2).36
A separate Phase I/II study by Touzeau et al examined 
the role of carfilzomib plus melphalan and prednisone 
in elderly patients with newly diagnosed MM. A total of 
24 patients .65 years of age were enrolled in the Phase I 
trial and treated with carfilzomib (20 mg/m2 with escalation 
to 45 mg/m2), melphalan 9 mg/m2, and prednisone 60 mg/m2. 
MTD was 36 mg/m2, and the subsequent Phase II trial 
enrolled 45 additional patients for a total of 69 patients. ORR 
was 89%, and at a median follow-up of 12 months, projected 
2-year OS was 89.9%. Carfilzomib plus melphalan and 
prednisone was well tolerated without significant peripheral 
neuropathy, and dosing at 40 mg/m2 was limited by grade 
3–4 fever and hypotension.37
In a subgroup analysis of a Phase I/II study by Jakubowiak 
et al, the efficacy of KRd was evaluated in elderly ($65 years 
of age) newly diagnosed MM patients. A total of 23 patients 
above the age of 65 years were enrolled. Patients were treated 
with KRd induction for eight cycles, followed by KRd main-
tenance for cycles 9–24 and then lenalidomide maintenance 
until progression or toxicity. The ORR was 100%, with the 
17 patients completing at least eight cycles of treatment, all 
achieving at least an nCR and 76% reaching an sCR. One- and 
2-year PFS rates were 97% and 92%, respectively.26
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High-risk cytogenetics
The role of cytogenetics in risk-stratifying prognosis for MM 
patients is well documented.38,39 Chromosomal alterations 
are well described, and are often complex in nature.40 These 
chromosomal aberrations have varied effects on outcomes 
for patients with MM.41
With the introduction of the proteasome inhibitor bort-
ezomib, evidence of its ability to overcome the adverse impact 
of some cytogenetic markers was noted.42–44 To evaluate the 
efficacy of carfilzomib in the management of patients with 
adverse cytogenetics, a prospective subgroup analysis of the 
Phase II PX-171-003-A1 trial was performed. In this study 
of 257 evaluable RRMM patients, cytogenetic profiles were 
available for 229 patients, of whom 62 (27.1%) had high-risk 
cytogenetics (defined as del17p13, t[4;14], t[14;16], or del13). 
The remaining 167 (72.9%) had standard-risk cytogenetic 
profiles, with similar baseline characteristics among the two 
arms. The ORR was comparable between the groups (25.8% 
versus 24.6% for high-risk and standard-risk,  respectively), 
with a trend of shorter response duration for high-risk 
patients (median duration of response of 5.6 months versus 
8.3 months). OS was significantly prolonged in the standard-
risk group, with the average patient living 9.3 months with 
high-risk cytogenetics and 19.0 months for standard-risk 
patients. These data, particularly the equivalent response 
rates, supported the efficacy of carfilzomib in overcoming 
some of the impact of high-risk cytogenetic abnormalities, 
but continued to show their negative effect on OS.45
Adverse effects
Given its high specificity and irreversible binding, the 
side-effect profile of carfilzomib differs significantly from 
bortezomib. A multitrial analysis was performed to assess 
the safety profile of single-agent carfilzomib in 526 patients 
with relapsed and/or refractory MM evaluating the four main 
Phase II trials assessing its efficacy (PX-171-003-A0 and -A1, 
PX-171-004, and PX-171-005).49 In these studies, carfilzomib 
was administered on days 1, 2, 8, 9, 15 and 16 in 28-day cycles, 
with the maximum dose administered being 27 mg/m2.15
The majority of patients evaluated in these trials were 
heavily pretreated with a median of four prior regimens. 
The most common grade 3–4 AEs were fatigue (55.5%), 
anemia (46.8%), and nausea (44.9%). By organ system, 
AEs were most common in the respiratory (69%), renal 
(33.1%), and cardiac (22.1%) systems. Hematologic toxici-
ties included thrombocytopenia (23.4%), anemia (22.4%), 
and  lymphopenia (18.1%). Febrile neutropenia was rare, 
occurring in 1.1% of patients. In comparison to bortezomib, 
peripheral neuropathy was uncommon (13.9%), with no grade 
4 or above reported, and all grade 3 peripheral neuropathy 
occurred in those with baseline grade 1 or 2 neuropathy.46
Cardiac toxicity has been a concern with carfilzomib 
since early studies. In the aggregate analysis, 38 patients 
(7.2%) developed cardiac failure events (CHF, pulmo-
nary edema, or decreased ejection fraction). There was 
no difference in mortality for patients who had baseline 
cardiac risk factors, and the rate of cardiac events did 
not increase with subsequent cycles. Any cardiac AE 
was seen in 22.1% of patients, with the most common 
being: hypertension (14.3%), arrhythmia (13.3%), and 
cardiomyopathy (1.7%). Complicating the evaluation of 
cardiac toxicity is the nature of MM patients, who often 
have multiple comorbidities and cumulative toxicities from 
prior therapies. In the evaluated trials, 73.6% of patients 
had a history of prior cardiac events, with 70% having 
baseline cardiac risk factors.46
Accompanying cardiac events, respiratory AEs were 
the most common nonhematologic organ system affected. 
Dyspnea was reported in 42.2% of patients; however, most 
episodes were grade 1–2, transient, and resolved without 
altering dosing. Grade 3 episodes of dyspnea occurred in 
only 4.8% of patients, and no grade 4 events were seen.46 
Hydration has been previously recommended with carfil-
zomib treatment, due to concerns of acute kidney injury, and 
it is suspected that some episodes of dyspnea were related to 
aggressive fluid administration in the setting of significant 
cardiac comorbidities. 
Key ongoing studies
As described earlier, many studies have investigated the role 
of carfilzomib in the RRMM setting, as well as in the newly 
diagnosed patient (Table 1). Ongoing Phase I, II, and III 
studies are evaluating carfilzomib as a combination agent in 
the treatment of RRMM, as well as newly diagnosed disease 
(Tables 2 and 3). Some of these trials have been reported and 
were discussed earlier, but many are actively enrolling and 
results are pending.
It seems likely that carfilzomib’s indication will grow, 
with the role of combination therapies expanding and its 
utility in the front-line setting evolving. Ongoing compara-
tive Phase III trials will likely further clarify carfilzomib’s 
potential benefits.
The currently enrolling ENDEAVOR trial47 is a random-
ized, multicenter, open-label Phase III study of carfilzomib 
and dexamethasone versus bortezomib plus dexamethasone 
for relapsed MM patients with no more than three prior 





Table 1 Key completed studies evaluating carfilzomib in MM




PX-171-001 (Phase i)  
carfilzomib (single agent)13
Hematologic malignancies  
(MM, NHL, wM, HL)
29 NR NR NR NR
PX-171-002 (Phase i)  
carfilzomib (single agent)12
Hematologic malignancies  
(MM, NHL, HL)
48 NR NR NR NR
PX-171-003-A0 (Phase iiB)  
carfilzomib (single agent)35
RRMM 46 16.7 0 (0 + 0) 3.5 NR
PX-171-003-A1 (Phase ii)  
carfilzomib (single agent)15
RRMM 266 23.7 5.5% (0.4% + 5.1%) 3.7 15.6
PX-171-004 (Phase ii)  
carfilzomib (single agent,  
20 mg/m2 versus 27 mg/m2)17
RRMM 129 42.4  
versus 52.2
17% (3.4% + 13.6%)  




PX-171-005 (Phase ii)  
carfilzomib (single agent)33
RRMM: renal  
dysfunction
50 25.5 0 (0 + 0) NR NR
PX-171-006 (Phase iB)  
carfilzomib + Rd22
Relapsed or  
progressive MM
40 62.5 35% (2.5% + 32.5%) 10.2 NR
PX-171-006 (Phase ii)  
carfilzomib + Rd21
Relapsed or  
progressive MM
52 76.9 42.2% (5.7% + 36.5%) 28.7 37
PX-171-007 (Phase iB/ii)  
carfilzomib (single agent)  
dose-expansion cohort16
Relapsed MM, solid  
tumors or lymphoma
33 55 28% (5% + 23%) 7 NR
Carfilzomib + Rd (Phase i/ii)26 Newly diagnosed 53 98 81% (62% + 19%) NR NR
Carfilzomib + clarithromycin +  
Rd (Phase i)27
Newly diagnosed 24 87 61% (13% + 48%) NR NR
FOCUS: PX-171-011 (Phase iii)  
carfilzomib versus best 
supportive care18
RRMM 315 NR NR NR NR
ASPiRe: PX-171-009 (Phase iii)  
carfilzomib + lenalidomide +  
dexamethasone versus  
lenalidomide + dexamethasone 
Planned interim analysis25
Relapsed MM 792 NR NR 26.3  
versus 17.6
NR
Abbreviations: ORR, overall response rate; CR, complete response; vGPR, very good partial response; PFS, progression-free survival; OS, overall survival; RRMM, relapsed 
and refractory multiple myeloma; NHL, non-Hodgkin’s lymphoma; WM, Waldenström’s macroglobulinemia; Rd, Revlimid and dexamethasone; NR, not reported.
Table 2 Key ongoing trials in newly diagnosed multiple myeloma (MM)
Regimen Population Authors Patients Phase
Carfilzomib + bendamustine + dexamethasone Newly diagnosed Lentzsch et al49 34 i/iiB
Carfilzomib + high-dose melphalan Transplant-eligible (preparative regimen) Costa et al50 58 i/iiA
Carfilzomib + melphalan + prednisone versus  
bortezomib + melphalan + prednisone (CLARiON)
Transplant-ineligible, newly diagnosed Facon et al48 882 iii
initial and posttransplant treatment with  
carfilzomib + revlimid + dexamethasone
Newly diagnosed, transplant-eligible,  
pre- and post-ASCT
Jakubowiak et al51 44 ii
Carfilzomib + lenalidomide + dexamethasone Smoldering MM (high risk) Landgren et al52 30 ii
Abbreviation: ASCT, autologous stem cell transplantation.
therapies. Patients must have had at least one prior therapy 
to which a response was recorded. Given carfilzomib’s 
improved safety profile and increased specificity, this will 
compare the outcomes and safety of bortezomib versus 
carfilzomib in relapsed MM patients. The primary outcome 
is PFS.
The CLARION trial is a Phase III study of carfilzomib, 
melphalan, and prednisone versus bortezomib, melphalan, 
and prednisone in newly diagnosed MM patients who are 
ineligible for transplant. The primary outcome is PFS, with 
efficacy and safety as key secondary outcomes.48
Conclusion
Significant changes in the management of MM over the past 
several decades have greatly improved outcomes. Despite 
many advances, MM remains an incurable disease. The 
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development of new drugs and novel combinations is key to 
continued progress.
Current data show that carfilzomib is an active and tolerable 
agent in the treatment of RRMM. Evidence for its efficacy and 
safety continue to grow. Its role in the  bortezomib-refractory 
patient was clearly illustrated in the PX-171-003-A1 trial, 
making it a viable and effective option for patients who were 
previously refractory to proteasome inhibition.
While numerous Phase II trials have shown it to have 
excellent response rates and a tolerable safety profile, initial 
Phase III studies are just now being reported. While aggregate 
results are encouraging, there continues to be much to learn 
about carfilzomib’s role in the management of the newly 
diagnosed patient, as well as its efficacy and tolerability as 
combination therapy. Further studies will continue to clarify 
the optimal dosing regimen and technique to maximize safety 
and efficacy.
The role of carfilzomib in the setting of emerging oral 
proteasome inhibitors remains to be seen. While patient pref-
erences may strongly favor oral options, their comparative 
efficacy and side-effect profiles are still under  investigation. 
It is likely there will continue to be a clear role for parenteral 
proteasome inhibitors despite the advent of oral options. 
Further questions yet to be answered include the role of 
carfilzomib in the maintenance setting and the variable 
utility of proteasome inhibitors in the era of personalized 
medicine.
Overall, carfilzomib represents an excellent option for 
patients with MM. We expect its indication to grow and 
its regulatory approval to expand outside the US. As data 
continue to accumulate supporting its efficacy and safety, it 
will maintain its role as a backbone of treatment.
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